Vaskuläre Demenz und Hypertonie

Stephan Lüders; Joachim Schrader

doi:10.1055/s-0041-105598

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2015; 140(21): 1599-1603
DOI: 10.1055/s-0041-105598

Dossier

Schlaganfall / vaskuläre Demenz

Vaskuläre Demenz und Hypertonie

Dementia and hypertension

Authors

Stephan Lüders

¹Innere Medizin, Nephrologie, Geriatrie, St. Josefs-Hospital, Cloppenburg
Joachim Schrader

¹Innere Medizin, Nephrologie, Geriatrie, St. Josefs-Hospital, Cloppenburg

Abstract

Zusammenfassung

Dementielle Erkrankungen sind in den kommenden Jahren eine wachsende Herausforderung für unser Gesundheitssystem. Da es bislang keine therapeutischen Möglichkeiten gibt, um eine manifeste Demenz effektiv zu behandeln, sind Maßnahmen zur Primärprävention von herausragender Bedeutung. Zu den gesicherten Risikofaktoren für vaskuläre Demenzen gehört die arterielle Hypertonie. Auch bei Patienten mit Alzheimerdemenz führt eine Hypertonie vermutlich dazu, dass sich die kognitive Situation schnell verschlechtert. Eine konsequente Blutdruckeinstellung, spätestens im mittleren Lebensalter, ist eine entscheidende Möglichkeit zur Prävention kognitiver Funktionsverluste. Darüberhinaus ist es wichtig, auch die anderen bekannten kardiovaskulären Risikofaktoren einzustellen. Regelmäßige körperliche Aktivität und Pflege sozialer Kontakte sind die Basis der Präventionsmöglichkeiten. Eine rechtzeitige medikamentöse antihypertensive Therapie kann das Fortschreiten von kognitiven Funktionseinbußen zumindest verlangsamen und so den Eintritt einer Demenz z. T. verhindern.

Abstract

Dementia and associated diseases will have increasing impact on economical and social system in most countries. As long as no causal therapy for dementia exists, primary prevention, diagnosis and control of risk factors for dementia are crucial. Uncontrolled hypertension is one of the most important risk factors for vascular dementia. An early antihypertensive treatment may reduce cognitive impairment or at least prolong the time to onset of dementia.

Schlüsselwörter

Hypertonie - Blutdruck - Demenz - Kognitive Funktion - vaskuläre Demenz

Keywords

hypertonia - blood pressure - dementia - cognitive function - vascular dementia

Full Text

References

Literatur
1 Deutsches Institut für Medizinische Information und Dokumentation (DIMDI). Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme. 10.. Revision German Modification Version 2015. https://www.dimdi.de/static/de/klassi/icd-10-gm/kodesuche/onlinefassungen/htmlgm2015/ (letzter Zugriff: 7. 9. 2015)
2 Gauthier S, Reisberg B, Zaudig M et al. Mild cognitive impairment. Lancet 2006; 367: 1262-1270
3 Hachinski V, Iadecola C, Petersen RC et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006; 37: 2220-2241
4 Van Straaten ECW, Scheltens P, Knol DL et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke 2003; 34: 1907-1912
5 Schneider JA, Arvanitakis Z, Bang W et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-2204
6 Gutzmann H, Qazi A. Depression associated with dementia. Z Gerontol Geriat 2015; 48: 305-311
7 Kalbe E, Calabrese P, Kohn N et al. Screening for cognitive deficits in Parkinson’s disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord 2008; 14: 93-101
8 Frisoni GB, Bocchetta M, Chételat G et al. Imaging markers for Alzheimer disease: Which vs how. Neurology 2013; 81 (05) 487-500
9 Savva GM, Wharton SB, Ince PG et al. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302-2309
10 DGN. Leitlinien für Diagnostik und Therapie in der Neurologie: Diagnose und Therapie von Demenzen. 2009; http://www.dgn.org/images/red_leitlinien/LL_2012/pdf/ll_15_2012_diagnose_und_therapie_von_demenzen.pdf (letzter Zugriff: 7. 9. 2015)
11 Kessler J, Calabrese P, Kalbe E et al. DemTect: A new screening method to support diagnosis of dementia. Psycho 2000; 26: 343-347
12 Takata Y, Ansai T, Soh I et al. Cognitive function and 10 year mortality in an 85 year-old community-dwelling population. Clin Interv Aging 2014; 9: 1691-1699
13 Wiederkehr S, Simard M, Fortin C et al. Validity of the clinical critera for vascular dementia: A critical review. Part II. J Neuropsychiatry Clin Neurosci 2008; 20: 162-177
14 DGN. Leitlinien für Diagnostik und Therapie in der Neurologie: Diagnostik und Therapie von Gedächtnisstörungen Entwicklungsstufe. 2012. http://www.awmf.org/uploads/tx_szleitlinien/030-124l_S2e_Ged%C3%A4chtnisst%C3%B6rungen_Diagnostik_Therapie_2012-verl%C3%A4ngert.pdf (letzter Zugriff: 7. 9. 2015)
15 Lüders S, Schrader J, Zidek W et al. Ambulatory blood pressure measurement in prehypertension: Analysis of the PHARAO-Study: Prevention of Hypertension with the ACE-inhibitor Ramipril in patients with high-normal blood pressure – a prospective, randomised, controlled prevention trial of the German Hypertension League. J Hypertension 2008; 26: 1487-1496
16 Lüders S, Dechend R, Eckert S et al. 24-h-Langzeitblutdruckmessung (ABDM). Der Kardiologe 2013; 7: 194-208
17 Mossello E, Pieraccioli M, Nesti N et al. Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. JAMA Intern Med 2015; 175: 578-585
18 Rönnemaa E, Zethelius B, Lannfelt L et al. Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement Geriatr Cogn Disord 2011; 31: 460-466
19 Lüders S, Saathoff U, Haller H et al. Häufigkeit kognitiver Funktionsstörungen bei Patienten mit Begleiterkrankungen – Ergebnisse des DemTect-Registers der Schlaganfall-Kommission der Deutschen Hypertonie-Gesellschaft. Berlin: DHL-Kongress; 2012
20 Zieschang T, Hauer K, Schwenk M. Körperliches Training bei Menschen mit Demenz. Dtsch Med Wochenschr 2012; 1370: 1552-1555
21 Hess NCL, Dieberg G, McFarlane JR et al. The effect of exercise intervention on cognitive performance in persons at risk of, or with, dementia: A systematic review and meta-analysis. Healthy Aging Research 2014; 3: 3
22 Brayne C, Ince PG, Keage HA et al. Education, the brain and dementia: neuroprotection or compensation. Brain 2010; 133: 2210-2216
23 Leys D, Henon H, Mackowiak-Cordoliani MA et al. Poststroke dementia. Lancet Neurol 2005; 4: 752-759
24 Mellon L, Brewer L, Hall P et al. Cognitive impairment six months after ischaemic stroke: a profile from the ASPIRE-S study. BMC Neurol 2015; 15: 31
25 Dufouil C, Godin O, Chalmers J et al. Cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke 2009; 40: 2219-2221
26 Sierra C, De la Sierra A, Mercader J et al. Silent cerebral white matter lesions in middle-aged essential hypertensive patients. J Hypertens 2002; 20: 519-524
27 Watanabe N, Imai Y, Nagai K et al. Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese. Stroke 1996; 27: 1319-1327
28 Launer LJ, Ross GW, Petrovitch H et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49-55
29 Freitag MH, Peila R, Masaki K et al. Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study. Stroke 2006; 37: 33-37
30 Kivipelto M, Helkala EL, Laakso MP et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137: 149-155
31 Launer LJ, Masaki K, Petrovitch H et al. The association between midlife blood pressure levels and late-life cognitive function. JAMA 1995; 274: 1846-1851
32 Morris MC, Scherr PA, Hebert LE et al. Association of incident Alzheimer’s disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001; 58: 1640-1646
33 Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487-499
34 Knecht S, Wersching H, Lohmann H et al. High-normal blood pressure is associated with poor cognitive performance. Hypertension 2008; 51: 663-668
35 Vermeer SE, Prins ND, Heijer den T et al. Silent brain infarcts and the risk of fementia and cognitive decline. N Engl J Med 2003; 348: 1215-1222
36 Bernick C, Kuller L, Dulberg C et al. Silent MRI infarcts and the risk of future stroke: The cardiovascular health study. Neurology 2001; 57: 1222-1229
37 Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 2010; 68: S74-87
38 Beauchet O, Celle S, Roche F et al. Blood pressure levels and brain volume reduction: a systematic review and meta-analysis. J Hypertens 2013; 31: 1502-1516
39 Skoog I, Lernfelt B, Landahl S et al. A 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145
40 Stewart R, Xue QL, Masaki K et al. Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension 2009; 54: 233-240
41 Kilander L, Nyman H, Boberg M et al. Hypertension is related to cognitive impairment: A 20-year follow-up of 999 men. Hypertension 1998; 31: 780-786
42 Sharp SI, Aarsland D, Day S et al. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry 2011; 26: 661-669
43 Ross GW, Petrovitch H, White LR et al. Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology 1999; 53: 337-343
44 Ueda K, Kawano H, Hasuo Y et al. Prevalence and etiology of dementia in a Japanese community. Stroke 1992; 23: 798-803
45 Yoshitake T, Kiyohara Y, Kato I et al. Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995; 45: 1161-1168
46 Prince M, Albanese E, Guerchet M. World Alzheimer Report 2014. Dementia and risk reduction. An analysis of protective and modifiable factors. London: Alzheimer’s Disease International (ADI); 2014
47 Power MC, Weuve J, Gagne JJ et al. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology 2011; 22: 646-659
48 Meng XF, Yu JT, Wang HF et al. Midlife vascular risk factors and the risk of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 2014; 42: 1295-1310
49 Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 2011; 10: 819-828
50 Norton S, Matthews FE, Barnes DE et al. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol 2014; 13: 788-794
51 Kivipelto M, Helkala EL, Laakso MP et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-1451
52 Wu C, Zhou D, Wen C et al. Relationship between blood pressure and Alzheimer‘s disease in Linxian County, China. Life Sci 2003; 72: 1125-1133
53 Whitmer RA, Sidney S, Selby J et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277-281
54 Ninomiya T, Ohara T, Hirakawa Y et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension 2011; 58: 22-28
55 Corrada M, Hayden KM, Bullain SS et al. Age of onset of hypertension and risk of dementia in the oldest-old: The 90+ Study. Alzheimers Dement 2014; 10: P501
56 McGuinness B, Todd S, Passmore P et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009; 4 CD004034
57 Forette F, Seux M-L, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-1351
58 Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment. New evidence from the systolic hypertension in Europe (Syst-Eur) Study. Arch Int Med 2002; 162: 2046-2052
59 Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069-1075
60 Haag MDM, Hofman A, Koudstaal PJ et al. Duration of antihypertensive drug use and risk of dementia. A prospective cohort study. Neurology 2009; 72: 1727-1734
61 Stewart R, Xue QL, Masaki K et al. Change in blood pressure and incident dementia a 32-year prospective study. Hypertension 2009; 54: 233-240
62 Peila R, White LR, Masaki K et al. Reducing the risk of dementia. Efficacy of long-term treatment of hypertension. Stroke 2006; 37: 1165-1170
63 Sugiyama T, Lee JD, Shimizu H et al. Influence of treated blood pressure on progression of silent cerebral infarction. J Hypertens 1999; 17: 679-684
64 Zanchetti A, Liu L, Mancia G et al. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension – Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. J Hypertens 2014; 32: 1888-1897
65 Böhm M, Schumacher H, Leong D et al. Systolic blood pressure variation and mean heart rate is associated withcognitive dysfunction in patients with high cardiovascular risk. Hypertension 2015; 65: 651-661
66 Lehrl S, Gräßel E, Eicke C. Wirkung von Felodipin bei hypertonen Patienten mit leichten Hirnleistungsstörungen in einer randomisierten Doppelblindstudie. Dtsch med Wochenschr 2000; 125: 1350-1356
67 Tedesco MA, Ratti G, Mennella S et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertension 1999; 12: 1130-1134
68 Duron E, Rigaud AS, Dubail D et al. Effects of Antihypertensive Therapy on Cognitive Decline in Alzheimer’s Disease. Am J Hypertens 2009; 22: 1020-1024
69 Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683-689
70 Van der Wardt V, Logan P, Conroy S et al. Antihypertensive treatment in people with dementia. J Am Med Dir Assoc 2014; 15: 620-629
71 Beishon LC, Harrison JK, Harwood RH et al. The evidence for treating hypertension in older people with dementia: a systematic review. J Hum Hypertens 2014; 28: 283-287
72 Ohrui T, Tomita N, Sato-Nakagawa T et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-1325
73 Kaiser EA, Lotze U, Schäfer HH. Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?. Clin Interven Aging 2014; 9: 459-475
74 Inaba S, Iwai M, Furuno M et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin / angiotensinogen transgenic mice. Hypertension 2009; 53: 356
75 Wright JW, Harding JW. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer’s disease. JRAAS 2008; 9: 226-237
76 Xie W, Zhu D, Ji L et al. Angiotensin-(1–7) improves cognitive function in rats with chronic cerebral hypoperfusion. Brain Res 2014; 1573: 44-53
77 Sink KM, Leng X, Williamson J et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension. Arch Intern Med 2009; 169: 1195-1202
78 Chiu WC, Ho WC, Lin MH et al. Angiotension receptor blockers reduce the risk of dementia. J Hypertens 2014; 32: 938-947
79 Fogari R, Preti P, Mugellini A et al. Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients. Am J Hypertens 2002; 15: 36A
80 Levi Marpillat N, Macquin-Mavier I, Tropeano AI et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 2013; 31: 1073-1082
81 Schrader J, Lüders S, Kulschewski A et al. Morbidity and mortality after stroke, Eprosartan compared with Nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226
82 Gelber RP, Ross GW, Petrovich H et al. Antihypertensive medication use and risk of cognitive impairment: The Honolulu-Asia Aging Study. Neurology 2013; 81: 888-895